Superworth

STERIS STE

Medical - Specialties, Healthcare
$231.42
−0.83%
Market cap
$22.6B
PE
28.3×
7y median 40.5×
Forward PE
20.2×
10y median 24.3×
Price to sales
3.7×
EV/EBIT
21.1×
Revenue, 12 months
$6B
+8% on a year ago
Net margin
13.3%
Free cash flow yield
4.1%

STERIS trades at 28.3× trailing earnings, cheaper than 94% of the last ten years. Revenue was $6B over the last twelve months, up 8% on a year earlier with a 13% net margin.

Charts

Financials

Income statement for STE, by quarter
Income statementQ2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
$1.2B+14%$1.3B+17%$1.4B+11%$1.3B+8%$1.3B+7%$1.4B+6%$1.5B+4%$1.4B+9%$1.5B+10%$1.5B+9%$1.6B+7%$1.5B+7%
Cost of revenue$692M+14%$737.7M+16%$836.5M+14%$707.1M+8%$750.1M+8%$760.2M+3%$839.3M+0%$763.1M+8%$814.4M+9%$840.7M+11%$891.2M+6%$808.6M+6%
Gross profit$546.2M+13%$560M+17%$582.9M+7%$572.4M+8%$578.8M+6%$610.3M+9%$641.2M+10%$628M+10%$645.9M+12%$655.5M+7%$697.1M+9%$684.2M+9%
R&D$26.3M+5%$25.3M−1%$27.5M+4%$25.6M+4%$27M+3%$27.4M+8%$27.7M+1%$26.4M+3%$28.2M+4%$29.5M+8%$28.8M+4%$28.6M+8%
SG&A$328.4M+2%$308.3M+1%$309.1M−8%$335.6M+10%$329.3M+0%$335.4M+9%$333.9M+8%$353.8M+5%$349.7M+6%$352.3M+5%$351.8M+5%$369.7M+5%
$191.6M$226.5M+19%$220.3M−2%$185.5M−6%$219.7M+15%$245.3M+8%$216.2M−2%$246M+33%$265.8M+21%$273.2M+11%$316.8M+47%$285.8M+16%
Interest expense$36.9M+41%$38.9M+36%$36.1M+18%$30.4M−6%$19.7M−47%$19.1M−51%$17.1M−53%$15.9M−48%$14.9M−24%$14.9M−22%$15.1M−12%$15.8M−1%
Pre-tax income$155.9M−2%$189.6M+11%$190.6M−6%$175.2M+5%$194.9M+25%$228.7M+21%$197.3M+4%$231.9M+32%$253.1M+30%$257.8M+13%$304.5M+54%$273.5M+18%
$35.1M−1%$41M+1%$37.3M+76%$35.3M−3%$43.5M+24%$55.4M+35%$50.5M+35%$53.9M+53%$60.6M+39%$63.5M+15%$84.2M+67%$72.5M+35%
Net income$115.3M$140.7M+14%−$1.4M$145.4M+18%$150M+30%$173.5M+23%$145.7M$177.4M+22%$191.9M+28%$192.9M+11%$220.2M+51%$200.1M+13%
$1.16$1.42+15%−$0.01$1.46+17%$1.51+30%$1.75+23%$1.48$1.79+23%$1.94+29%$1.96+12%$2.24+51%$2.04+14%
99.4M−1%99.4M−1%98.9M−1%99.4M+0%99.2M−0%98.9M−1%98.7M−0%98.8M−1%98.8M−0%98.6M−0%98.4M−0%97.9M−1%

EPS, diluted: 6 periods, Q1 FY20 to Q4 FY26: quarter's net income to common over its shares, to the cent.

Diluted shares: 6 periods, Q4 FY19 to Q4 FY26: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution. Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Estimates

Next earnings report: .

QuarterRevenueRangeEPSRangeAnalysts
Q2 FY27$1.6B$1.6B to $1.6B$2.68$2.67 to $2.694
Q3 FY27$1.6B$1.6B to $1.6B$2.81$2.80 to $2.844
Q4 FY27$1.7B$1.7B to $1.7B$3.15$3.13 to $3.181
Q1 FY28$1.6B$1.6B to $1.6B$2.83$2.81 to $2.861
Q2 FY28$1.7B$1.7B to $1.7B$2.95$2.93 to $2.981
Q3 FY28$1.7B$1.7B to $1.7B$3.07$3.05 to $3.101
Q4 FY28$1.8B$1.8B to $1.8B$3.44$3.42 to $3.472
Q1 FY29$1.7B$1.7B to $1.7B$3.07$3.05 to $3.102

Peers

Companies in Healthcare nearest STERIS' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
STESTERIS$22.7B28.4×40.5×20.2×3.8×+8%13.3%
THCTenet Healthcare$21.5B10.3×11.1×12.8×1.0×+5%10.3%
INCYIncyte$24.3B15.3×36.5×51.3×4.2×+27%27.7%
ALNYAlnylam Pharmaceuticals$21.2B26.7×68.2×18.9×4.4×+95%16.8%
UTHRUnited Therapeutics$25.9B21.6×14.2×22.6×8.2×+2%41.6%
DGXQuest Diagnostics$27.5B24.9×19.3×n/m2.3×+9%9.5%
ZBHZimmer Biomet$18.6B23.7×31.2×n/m2.2×+9%9.5%
MEDPMedpace$18.1B38.0×34.5×n/m6.5×+25%17.7%
WSTWest Pharmaceutical Services$28.9B52.5×45.9×44.2×8.7×+12%17.0%
LHLabcorp$28.9B29.4×19.5×18.8×2.0×+6%7.0%
EXELExelixis$17.4B22.1×22.7×n/m7.1×+9%35.3%
Peer median$22.9B24.3×27.0×20.7×4.3×+9%16.9%

More on STERIS

Each number over time

Its groups

About

Industry
Medical - Specialties
Sector
Healthcare

Valuation data, not investment advice. Prices as of .